Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Neural Group, Last Fiscal Year's Ordinary Profit Turns to Loss, Current period performance is undisclosed.
4056 Neural Group Inc. 【J-GAAP】
Earnings ReportNeural Group Inc. <4056> [TSE Growth] announced its financial results after the market closed on February 13th (15:30). The consolidated ordinary profit/loss for the fiscal year ended December 2025 turned into a loss of 0.04 billion yen (compared to a profit of 0.01 billion yen in the previous period), falling below the forecast of a 0.14 billion yen, and turning into a loss. Furthermore, the company projects revenue of 5.30 billion yen for the fiscal year ending December 2026.
In the most recent three-month period, from October to December (4Q), the consolidated ordinary profit/loss turned to a loss of 0.03 billion yen (compared to a profit of 0.11 billion yen in the same period last year). The operating profit/loss margin drastically worsened from 11.6% in the same period last year to -3.9%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2023 | 3,178 | -658 | -686 | -650 | -43.7 | 0 | Feb 14, 2024 | J-GAAP |
| Dec, 2024 | 3,564 | 35 | 11 | -60 | -4.0 | 0 | Feb 14, 2025 | J-GAAP |
| Dec, 2025 | 3,299 | -6 | -46 | -107 | -6.8 | 0 | Feb 13, 2026 | J-GAAP |
| YoY | -7.4% | - | - | -78.3% | -70.3% |
Full Year Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2025 Guidance | 3,700 | 160 | 140 | 40 | 2.3 | 0 | Feb 14, 2025 | J-GAAP |
| Dec, 2025 Results | 3,299 | -6 | -46 | -107 | -6.8 | 0 | Feb 13, 2026 | J-GAAP |
| Revision Rate | -10.8% | - | - | - | - |
Current Period Guidance
H1 Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jan - Jun, 2025 | 1,712 | 1 | -9 | -38 | -2.5 | 0 | Aug 8, 2025 | J-GAAP |
| Jan - Jun, 2026 Guidance | ー | ー | ー | ー | - | 0 | Feb 13, 2026 | J-GAAP |
| YoY | - | - | - | - | - |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2024 | 3,564 | 35 | 11 | -60 | -4.0 | 0 | Feb 14, 2025 | J-GAAP |
| Dec, 2025 | 3,299 | -6 | -46 | -107 | -6.8 | 0 | Feb 13, 2026 | J-GAAP |
| Dec, 2026 Guidance | 5,300 | ー | ー | ー | - | 0 | Feb 13, 2026 | J-GAAP |
| YoY | +60.7% | - | - | - | - |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 996 | 116 | 111 | 93 | 6.2 | 11.6 | Feb 14, 2025 | J-GAAP |
| Jan - Mar, 2025 | 825 | -9 | -14 | -29 | -1.9 | -1.1 | May 12, 2025 | J-GAAP |
| Apr - Jun, 2025 | 887 | 10 | 5 | -9 | -0.6 | 1.1 | Aug 8, 2025 | J-GAAP |
| Jul - Sep, 2025 | 823 | 23 | 0 | -14 | -0.9 | 2.8 | Nov 10, 2025 | J-GAAP |
| Oct - Dec, 2025 | 764 | -30 | -37 | -55 | -3.5 | -3.9 | Feb 13, 2026 | J-GAAP |
| YoY | -23.3% | - | - | - | - |
Related Articles
LUCKLAND, 3% Increase in Ordinary Profit, Update Record High for Second Consecutive Term, Dividend Raised by 20 Yen
Delta-Fly Pharma, Apr-Dec (Cumulative 3Q) Net Income Loss Narrows, Oct-Dec Net Income Loss Widens
Future Innovation Group, 21% Increase in Ordinary Profit, Record High for The First Time in Four Years
TAIKO PHARMA, Last Fiscal Year's Ordinary Profit Exceeds Expectations, 8% Increase in The Current Fiscal Year, Resuming Dividends at 3.3 Yen for the First Time in five terms., This Fiscal Year to Increase Dividend by 0.2 Yen
MS&AD Insurance, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 7%, Exceeds Full-Year Plan
BrightPath Biotherapeutics, Apr-Dec (Cumulative 3Q) Net Income Loss Widens, Oct-Dec Net Income Loss Widens
VELTRA, 3.7 times Increase in Ordinary Profit for The Current Fiscal Year
Dynamic Map, Apr-Dec (Cumulative 3Q) Ordinary Profit Loss Widens, Oct-Dec Ordinary Profit Loss Widens
LIFE CREATE, Ordinary Profit Forecast for the Fiscal Year Revised Downward to an Unexpected 41% Decrease
Asia Air Survey, Oct-Dec (1Q) Operating Profit Turns to Profit